A

AIRNA

60 employees

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.

Investor insights

Funding rounds participated in

$60M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2021

Funding rounds raised

Total raised

$60M

from 2 investors over 1 rounds

A

AIRNA raised $60M on August 31, 2024

Investors: Forbion Capital Partners and + 3 Other investors